ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.

Lilly

Status and phase: Completed; Phase 2

Conditions: Carcinoma, Non-Small-Cell Lung

Treatments: Drug: ALIMTA; Drug: Carboplatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00051493

6142

H3E-MC-JMEZ

Details and patient eligibility

About

The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and Carboplatin on you and your non-small cell lung cancer.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• You have a diagnosis of non-small cell lung cancer.
• You have received no prior chemotherapy.
• You have at least one measurable lesion.
• You have an adequate performance status.
• You are at least 18 years of age.

Exclusion criteria

• You have previously received chemotherapy for your lung cancer.
• You have received radiation within the last 30 days.
• You have active infection or other serious condition.
• You have brain metastasis.
• You have recently lost a significant amount of weight.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)